In-vitro bactericidal activity of quinupristin/dalfopristin alone and in combination against resistant strains of Enterococcus species and Staphylococcus aureus

Journal of Antimicrobial Chemotherapy

Volumn 39, Issue SUPPL. A, 1997, Pages 33-39

  Lena Kang, S ^a,b   Rybak, Michael J ^c,d  

^a UNIVERSITY OF THE PACIFIC   (United States)

^b SANTA BARBARA COTTAGE HOSPITAL   (United States)

^c DETROIT RECEIVING HOSPITAL   (United States)

^d WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DALFOPRISTIN; GENTAMICIN; OFLOXACIN; QUINUPRISTIN; STREPTOGRAMIN DERIVATIVE; VANCOMYCIN;

ARTICLE; BACTERICIDAL ACTIVITY; DRUG POTENTIATION; ENTEROCOCCUS; ENTEROCOCCUS FAECALIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTIDRUG RESISTANCE; NONHUMAN; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; COLONY COUNT, MICROBIAL; DRUG RESISTANCE, MULTIPLE; DRUG THERAPY, COMBINATION; ENTEROCOCCUS; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCUS AUREUS; TIME FACTORS; VANCOMYCIN; VIRGINIAMYCIN;

EID: 0345219438     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/39.suppl_1.33     Document Type: Article

References (33)

1. Schaberg, D. R., Culver, D. H. & Gaynes, R. P. (1991). Major trends in the microbial etiology of nosocomial infection. American Journal of Medicine 91, Suppl. 38, 72-5S.
2. Thornsberry, C. (1996). Emerging resistance in clinically important Gram-positive cocci. Western Journal of Medicine 164, 28-32.
3. Centers for Disease Control. (1993). Nosocomial enterococci resistant to vancomycin - United States, 1983-1993. Mortality and Morbidity Weekly Report 42, 597-9.
4. Centers for Disease Control. (1995), Statewide surveillance for antibiotic-resistant bacteria-New Jersey, 1992-1994. Mortality and Morbidity Weekly Report 44, 504-6.
5. Edmond, M. B., Ober, J. F., Weinbaum, D. L., Pfaller, M. A., Hwang, T., Sanford, M. D. et al. (1995). Vancomycin-resistant Enterococcus faecium bacteremia: risk factors for infection. Clinical Infectious Diseases 20, 1126-33.
6. Morris, J. Q., Shay, D. K., Hebden, J. N., McCarter, R. J., Perdue, B. E., Jarvis, W. et al. (1995). Enterococci resistant to multiple antimicrobial agents, including vancomycin. Annals of Internal Medicine 123, 250-9.
7. Voss, A. & Doebbeling, B. N. (1995). The worldwide prevalence of methicillin-resistant Staphylococcus aureus. International Journal of Antimicrobial Agents, 5, 101-6.
8. Aumercier, M. S., Bouhallab, S., Capmau, M. & LeGoffic, F. (1992). RP 59500: a proposed mechanism for its bactericidal activity. Journal of Antimicrobial Chemotherapy 30, Suppl. A, 9-14.
9. Pass, R. J. (1991). In vitro activity of RP 59500, a semisynthetic injectable pristinamycin, against staphylococci, streptococci, and enterococci. Antimicrobial Agents and Chemotherapy 35, 553-9.
10. Archer, G. D., Auger, P., Doern, G. V., Ferraro, M. J., Fuchs, P. C., Jorgensen, J. H. et al. (1993). RP 59500, a new streptogramin highly active against recent isolates of North American staphylococci. Diagnostic Microbiology and Infectious Diseases 16, 223-6.
11. Collins, L. A., Malanoski, G. J., Eliopoulos, G. M., Wennersten, C. B., Ferraro, M. J. & Moellering, R. C. (1993). In vitro activity of RP 59500, an injectable streptogramin antibiotic, against vancomycin-resistant Gram-positive organisms. Antimicrobial Agents and Chemotherapy 37, 598-601.
12. Bouanchaud, D. H. (1992). Synergic activity and fractional inhibitory concentration (FIC) index of components or RP 59500, a new semisynthetic streptogramin. Journal of Antimicrobial Chemotherapy 30, Suppl. A, 95-9.
13. Kang, S. L. & Rybak, M. J. (1995). Pharmacodynamics of RP 59500 alone and in combination with vancomycin against Staphylococcus aureus in an in vitro-infected fibrin clot mode. Antimicrobial Agents and Chemotherapy 39, 1505-11.
14. Freeman, C., Robinson, A., Cooper, B., Mazens-Sullivan, M., Quintiliani, R. & Nightingale, C. (1995). In vitro antimicrobial susceptibility of glycopeptide-resistant enterococci. Diagnostic Microbiology and Infectious Diseases 21, 47-50.
15. National Committee for Clinical Laboratory Standards. (1990). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically - Second Edition: Approved Standard M7-A2. NCCLS, Villanova, PA.
16. Krogstad, D. J. & Moellering, R. C. (1986). Antimicrobial combinations. In Antibiotics in Laboratory Medicine (Lorian, V., Ed.), pp. 537-95. Williams & Wilkins, Baltimore, MD.
17. Etienne, S. D., Montay, G., Le Liboux, A., Frydman, A. & Garaud, J. J. (1992). A phase I, double-blind placebo-controlled study of the tolerance and pharmacokinetic behaviour of RP 59500. Journal of Antimicrobial Chemotherapy 30, Suppl. A, 123-31.
18. McGrath, B. J., Kang, S. L., Kaatz, G. W. & Rybak, M. J. (1994). Teicoplanin, vancomycin, and gentamicin bactericidal activity alone and in combination against Staphylococcus aureus in an in vitro pharmacodynamic model of infective endocarditis. Antimicrobial Agents and Chemotherapy 38, 2034-40.
19. Palmer, S. M. & Rybak, M. J. (1996). Pharmacodynamics of once- or twice-daily levofloxacin versus vancomycin, with or without rifampicin, against Staphylococcus aureus in an in vitro model with infected platelet-fibrin clots. Antimicrobial Agents and Chemotherapy 40, 701-5.
20. Engel, H. W., Soedirman, N., Rost, J. A., van Leeuwen, W. J. & van Embden, J. D. (1980). Transferability of macrolide, lincomycin, and streptogramin resistance between group A, B and D streptococci, Streptococcus pneumoniae, and Staphylococcus aureus. Journal of Bacteriology, 142, 407-13.
21. Leclercq, R., Derlot, E., Weber, M., Duval, J. &. Courvalin, P. (1989). Transferable vancomycin and teicoplanin resistance in Enterococcus faecium. Antimicrobial Agents and Chemotherapy 33, 10-15.
22. Noble, W. C., Virani, Z. & Cree, R. G. (1992). Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12202 to Staphylococcus aureus. FEMS Microbiology Letters 93, 195-8.
23. Archer, G. L. & Climo, M. W. (1996). Treatment of vancomycin-resistant staphylococcal infections. Annals of Pharmacothorapy 30, 288-90.
24. Johnson, C. C., Slavoski, L., Schwartz, M., May, P., Pitsakis, P. G., Shur, A. L. et al. (1995). In vitro activity of RP 59500 (quinupristin/dalfopristin) against antibiotic-resistant strains of Streptococcus pneumoniae and enterococci. Diagnostic Microbiology and Infectious Disease 21, 169-73.
25. Caron, F., Gold, H. S., Wennersten, C. B., Moellering, R. C. & Eliopoulos, G. C. (1996). Role of growth phase and of erythromycin susceptibility on the bactericidal effect of RP 59500 against VREF. In Program and Abstracts of the Third International Conference on the Macrolides, Azalides and Streptogramins, Lisbon.
26. Furlong, W. B. (1994). Therapy for enterococci with Van A/Van B resistance patterns using RP 59500 (quinupristin/dalfo- pristln). In Program and Abstracts of the Thirty-Fourth Interscience Conference on Antimicrobial Agents and Chemotherapy Orlando, 1994. Abstract M66, p.261. American Society for Microbiology, Washington, DC.
27. Linden, P., Pasculle, W., Kramer, D. & Dotterweich, L. (1996). Effect of quinupristin/dalfopristin on the outcome of vancomycin-resistant E. faecium bacteraemia: comparison with a control cohort. In Program and Abstracts of the Third International Conference on the Macrolides, Azalides and Streptogramins, Lisbon. Abstract 6.22.
28. Boswell, F. J., Andrews, J. M. & Wise, R. (1994). The post-antibiotic effect of RP 59500 on Staphylococcus aureus including strains with a raised MBC. Journal of Antimicrobial Chemotherapy 33, 1219-22.
29. Boswell, F. J., Sunderland, J., Andrews, J. M. & Wise, R. (1995). Time kill kinetics of RP 59500 (quinupristin/dalfopristin) on Staphylococcus aureus with and without a raised MBC evaluated using two methods. In Program and Abstracts of the Thirty-Fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1995. Abstract E123, p. 107. American Society for Microbiology, Washington, DC.
30. Caron, F., Kitzis, M., Gutmann, L., Cremieux, A., Maziere, B., Vallois, J. et al. (1992). Daptomycin or teicoplanin in combination with gentamicin for treatment of experimental endocarditis due to a highly glycopeptide-resistant isolate of Enterococcus faecium. Antimicrobial Agents and Chemotherapy 36, 2611-6.
31. French, P., Venuti, E. & Fraimow, H. S. (1993). In vitro activity of novobiocin against multiresistant strains of Enterococcus faecium. Antimicrobial Agents and Chemotherapy 37, 2736-9.
32. Pasculie, A. W., Linden, P. K., Wagener, W., McKnight, J. L. & Papafrangas, E. A. (1993). Susceptibility of vancomycin-resistant Enterococcus faecium (VREF) to alternative antimicrobial agents singly and in combination. In Program and Abstracts of the Thirty-Third Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, 1993. Abstract 1060, p.313. American Society for Microbiology, Washington, DC.
33. Nicolau, D. P., Marangos, M. N., Nightingale, C. H., Patel, K. B., Cooper, B. W., Quintiliani, R. et al. (1996). Efficacy of vancomycin and teicoplanin alone and in combination with streptomycin in experimental, low-level vancomycin-resistant, vanB-type Enterococcus faecalis endocarditis. Antimicrobial Agents and Chemotherapy 40, 55-60.